Articles tagged with Angiotensin Receptors
Researchers found that mice without the ANGPTL4 gene were protected from intestinal inflammation and colon tumors due to altered macrophage behavior. The study suggests that early-life inflammatory events can shape long-term immune programming, providing resistance to future challenges.
Researchers at Penn's School of Dental Medicine and Perelman School of Medicine found that ACE inhibitors can inhibit the activity of ACE2, a critical cardioprotective enzyme. This discovery has implications for human patients prescribed these medications, who may benefit from additional ACE2 treatment.
Research highlights correlation between preeclampsia and COVID-19 in pregnant women, identifying biomarkers for differential diagnosis. The review article emphasizes the pathophysiological similarities between the two conditions, including shared pathways involving the renin-angiotensin system and ACE2.
Continuation of renin-angiotensin system inhibitors before major noncardiac surgery was not associated with a higher rate of postoperative complications compared to discontinuation. The study aimed to investigate the impact of continued use of these medications on surgical outcomes.
Researchers propose a novel augmentation regimen, IPIAD, combining five generic non-oncology drugs with standard chemotherapy for pancreatic ductal adenocarcinoma. The IPIAD regimen uses repurposed drugs like irbesartan and azithromycin to potentially slow disease growth and improve outcomes.
A new study identifies nitric oxide as a key molecule in the β2-adrenergic receptor feedback loop, mediating airway relaxation. The research team discovered that preventing nitric oxide's feedback mechanism leads to a powerful airway relaxant. Mice with a specific mutation in the β2 AR gene are resistant to bronchoconstriction and asthma.
Researchers found that aerobic exercise improves autonomic regulation of the heart and contributes to proper functioning of the cardiovascular system. Walking for 45 minutes three times a week increased heart rate variability, a scientifically validated parameter to assess the functioning of the autonomic nervous system.
The study found that patiromer significantly lowers blood potassium levels in patients taking RAASi medications for heart failure. The results suggest that patiromer can be used to control excess potassium buildup in the blood, which is a common side effect of RAASi therapy.
Researchers found that females rely more heavily on aldosterone to regulate blood pressure, whereas males primarily use angiotensin II. This discovery could lead to targeted treatments for female hypertensive patients, improving treatment outcomes and reducing the risk of heart disease and stroke.
A recent study explores the dilemma of COVID-19, aging, and cardiovascular disease, examining the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with coronavirus disease 2019. The findings highlight the need for careful consideration of treatment options in this vulnerable population.
Researchers recommend continued use of ACE inhibitors and ARBs for COVID-19 patients due to cardiovascular benefits. The authors highlight the importance of considering individual patient risk factors in treatment decisions.
Recent research suggests that ACE inhibitors and angiotensin receptor blockers can have a beneficial effect on COVID-19 outcomes for hypertensive patients. A review of over 60 published studies found no evidence to support concerns about these drugs increasing the risk of infection or disease severity.
Researchers at Monash University have discovered that receptors can communicate and interact, affecting the therapeutic actions of relaxin. This finding has implications for clinical trials involving relaxin and other drugs acting on these receptors.
Scientists at Duke University and colleagues have identified four main shapes of the angiotensin receptor, which interact differently with various drugs. This breakthrough could lead to the development of more specific medications that target only the desired effects, reducing unwanted side effects.
Scientists have successfully mapped the active-state structure of the angiotensin II type 1 receptor, a critical drug target for regulating blood pressure and kidney function. The study provides insights into how this receptor activates and offers clues for developing new medications that activate rather than block the receptor.
An experimental compound appears to improve stroke outcomes by reducing lingering inflammation, leading to better memory and movement in its aftermath. The compound, known as compound 21, stimulates the angiotensin type 2 receptor, which aids blood vessel dilation, minimizes cell death, and reduces inflammation.
Research found that angiotensin II-induced hypertension increases with age due to heterodimerization of AT1R with P2Y6R. This altered signaling pathway converts cell proliferation to hypertrophy in vascular smooth muscle cells.
A study of over 30,000 patients found that not resuming blood pressure medication within two days of surgery significantly increases the risk of infections, pneumonia, heart failure, and kidney failure. Resuming ARBs sooner reduces these risks.
Using a sophisticated X-ray analysis, scientists revealed the molecular structure of the angiotensin receptor AT1R, an important regulator of blood pressure in humans. This discovery provides new insights into the mode of action and facilitates the development of new drugs with fewer side effects.
The PARADIGM-HF trial found LCZ696 to be superior to enalapril in reducing cardiovascular mortality and hospitalization for heart failure. The study showed a 20% reduction in death from cardiovascular causes and a 21% reduction in hospitalization for heart failure.
Researchers monitor blood pressure of 47 volunteers on Mount Everest and find a progressive increase in blood pressure with altitude. Telmisartan is effective in counteracting the effects of high altitude up to 3400 meters, but not at 5400 meters.
Researchers developed a double-stapled peptide that prevents RSV infection by stabilizing its structure, allowing for effective prevention in both cell culture and murine models. Additionally, intranasal and intratracheal delivery methods were found to be effective in preventing nasopulmonary infection.
A Swedish study found commonly used heart failure and high blood pressure medications can benefit patients with a rare type of heart failure. The use of ACE-inhibitors or angiotensin receptor blockers lowered mortality rates by 10% in HFPEF patients.
A study published in JAMA Network found that candesartan was linked to a lower risk of death at 1 and 5 years, compared to losartan, in patients with heart failure. The analysis of data from an HF registry involved 30,254 patients treated with either candesartan or losartan.
Researchers have uncovered a novel mechanism controlling blood pressure, shedding new light on the causes of pre-eclampsia. The study found a fine-tuning mechanism responsive to tissue oxygen changes, providing potential insights into prevention and treatment.
Biochemists at the University of Texas Medical School have found evidence that pre-eclampsia may be an autoimmune disease, with autoantibodies activating an angiotensin receptor that causes artery constriction. This could lead to novel diagnostic and therapeutic possibilities for the condition.
The study found that manipulating a specific signaling pathway in the AT1 receptor altered animal behavior, increasing salt intake without water consumption. This suggests that intracellular events can regulate behavioral states, providing new insights into angiotensin's role in mammalian behaviors.
The study found that BENICAR and Benicar HCT helped patients reach aggressive blood pressure goals, with nearly 69.3% achieving less than or equal to 130/85 mmHg after 16 weeks. Additionally, BENICAR was found to be more effective in reaching blood pressure goals compared to other ARBs like Cozaar and Diovan.
A new study has found that the starting dose of Lexapro is as effective as an optimally dosed Zoloft in treating depression. Patients treated with Lexapro experienced significant relief from depressive symptoms, with 75% achieving a 50% or better reduction in their Montgomery-Asberg Depression Rating Scale scores.
A new study suggests that patients with heart failure may only need one medication to target both beta-adrenergic and angiotensin receptors, rather than multiple blockers. This finding could lead to tailored treatment strategies for individual patients, reducing the risk of side effects.
The Val-HeFT study showed significant effects of an AT1-receptor blocker on mortality and morbidity in patients with heart failure when added to ACE inhibitor therapy. The CHARM study programme aims to provide more definitive data on the benefits of AT1-receptor blockers in treating heart failure.
Kenneth Bernstein has made significant contributions to understanding the renin-angiotensin system, a key regulator of blood pressure. His work has transformed the field, revealing new insights into the biology of angiotensin II and its effects on cardiovascular function.